Eli Lilly's Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86%
Eli Lilly's Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86%
On Monday, Eli Lilly And Co (NYSE:LLY) announced Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhibitor of lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease.
禮來公司（紐交所：LLY）週一宣佈了muvalaplin的2期結果，這是一種每日一次口服的選擇性脂蛋白(a) [Lp(a)]抑制劑，Lp(a)是一種遺傳性心臟病風險因素。
In the U.S., about 20% of people, or approximately 63 million individuals, have high levels of Lp(a).
在美國，約20%的人口，或大約6300萬人，患有高水平的Lp(a)。
Elevated Lp(a) levels can double or even triple the risk of a heart attack and are associated with other cardiovascular issues.
Lp(a)水平升高會使心臟病發作的風險翻倍甚至三倍，並與其他心血管問題相關。
Also Read: Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure
另請參閱：禮來公司的Zepbound/Mounjaro顯示對肥胖相關心力衰竭患者具有心血管益處。
The study demonstrated that muvalaplin significantly reduced elevated Lp(a) levels in adults, meeting its primary endpoint.
研究表明，muvalaplin明顯降低了成年人的高Lp(a)水平，實現了主要終點。
At the 12-week primary endpoint, muvalaplin (10 mg, 60 mg, and 240 mg) significantly reduced Lp(a) levels compared to placebo.
在爲期12周的主要終點處，muvalaplin（10毫克、60毫克和240毫克）較安慰劑顯著降低了Lp(a)水平。
The placebo-adjusted reductions were up to 85.8% using an intact Lp(a) assay and up to 70.0% using an apo(a) assay.
使用完整Lp(a)測定，安慰劑調整減少了高達85.8%，使用apo(a)測定，降低了高達70.0%。
- Specifically, the reductions were 47.6% (10 mg), 81.7% (60 mg) and 85.8% (240 mg) with the intact Lp(a) assay, and 40.4% (10 mg), 70.0% (60 mg) and 68.9% (240 mg) with the apo(a) assay.
- 具體來說，使用完整Lp(a)測定，減少了47.6%（10毫克），81.7%（60毫克）和85.8%（240毫克），使用apo(a)測定，減少了40.4%（10毫克），70.0%（60毫克）和68.9%（240毫克）。
Muvalaplin also met secondary endpoints for all three tested doses (10 mg, 60 mg, and 240 mg).
Muvalaplin在所有三個測試劑量（10毫克、60毫克和240毫克）中也達到了次要終點。
- The three tested doses achieved statistical significance for Lp(a) thresholds, and the 60 mg and 240 mg doses also achieved statistical significance for apoB reductions.
- 這三個測試劑量在Lp(a)閾值方面取得了統計學顯著性，而60毫克和240毫克劑量還在apoB減少方面取得了統計學顯著性。
These data also demonstrated:
這些數據還表明：
- Using the intact Lp(a) assay, the percentage of participants achieving normal Lp(a) levels of less than 125 nmol/L at week 12 was 64.2% (10 mg), 95.9% (60 mg), and 96.7% (240 mg), compared to 6.0% in the placebo group.
- Using the apo(a) assay, 38.9% (10 mg), 81.9% (60 mg), and 77.4% (240 mg) of participants achieved an Lp (a) level of less than 125 nmol/L, compared to 3.6% in the placebo group.
- ApoB levels were reduced at all doses, with placebo-adjusted reductions of 8.9% (10 mg), 13.1% (60 mg) and 16.1% (240 mg).
- 使用完整的Lp(a)測定，在第12周時，達到正常Lp(a)水平（小於125 nmol/L）的參與者百分比分別爲64.2%（10毫克）、95.9%（60毫克）和96.7%（240毫克），相比之下，安慰劑組爲6.0%。
- 使用apo(a)測定，在第12周時，38.9%（10毫克）、81.9%（60毫克）和77.4%（240毫克）的參與者達到Lp(a)水平低於125 nmol/L的水平，相比之下，安慰劑組爲3.6%。
- 在所有劑量下，Apob水平均有所降低，相對安慰劑分別降低了8.9%（10毫克）、13.1%（60毫克）和16.1%（240毫克）。
Adverse events were similar in both the muvalaplin and placebo groups.
不良事件在Muvalaplin組和安慰劑組中也是相似的。
Price Action: LLY stock is down 0.44% at $723.97 at the last check on Tuesday.
股價走勢：禮來股票在上週二最後收盤時下跌0.44%，報723.97美元。
- Walmart Q3 Earnings: Revenue Beat, eCommerce Growth Shines, Issues Bullish Outlook For FY25
- 沃爾瑪第三季度收益：營業收入超預期，電子商務增長強勁，對2025財年持樂觀展望。
Photo by Jonathan Weiss via Shutterstock
由Jonathan Weiss拍攝，通過shutterstock提供的照片
譯文內容由第三人軟體翻譯。
